Andrew Feinberg's 7 Stock Picks for 2013
Seven stocks from me this year: Five to buy, two to sell short.
Over the past year, the hedge fund I run beat the U.S. stock market by five percentage points. Alas, the news isn’t as good about my four picks in the January 2012 issue. They returned 6.2%, on average, eight points worse than Standard & Poor’s 500-stock index. I apologize for lousy selectivity.
In a desperate attempt to avoid a similar fate in 2013, I am picking seven stocks this time -- two to sell short (a bet on falling share prices) and five to buy. Let’s begin with the shorts (share prices are as of November 2).
Even though Salesforce.com (symbol CRM, $147) has a market value of $20 billion, the cloud-computing giant barely makes any money, and it sometimes resorts to accounting gimmicks to show a profit. The stock trades at a steep 74 times estimated earnings for the fiscal year that ends in January 2014. Insiders, as well as executives at companies acquired by Salesforce with its shares, have been selling like crazy. The stock could easily be cut in half.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The food is fine at Chipotle Mexican Grill (CMG, $262), but growth of same-store sales (sales at stores open at least one year) is slowing. That’s terrible news for a stock that trades at a high 25 times estimated 2013 earnings. Other negatives: Rival Taco Bell’s revamped menu is doing well, food costs are set to rise sharply, and many consumers are looking for healthier alternatives.
My buy suggestions. Let’s start with Ocwen Financial (OCN, $35). The stock soared 142% in 2012, but it still has room to grow. Ocwen services mortgages, so it’s partly a play on a resurgent housing market. In October, the company announced two deals -- one for the loan-servicing business of Residential Capital and the other for Homeward Residential, a mortgage servicer and originator. Analysts see Ocwen earning $4.49 per share in 2013, but I think profits will be much higher.
Fortress Investment Group (FIG, $4.55) is a New York City firm that manages hedge funds, private-equity funds and other accounts. Its stock traded as high as $34 in 2007, before plunging toward the abyss. Fortress’s funds have been performing well, and the firm is raking in billions of dollars in new money. In addition, because many formerly laggard funds have rebounded, Fortress is in a position to start collecting more in performance-incentive fees. If you subtract the cash and investments on Fortress’s balance sheet from its market value, the stock trades at just 3.5 times estimated 2013 profits.
A developer and homebuilder in the U.S. and Canada, Brookfield Residential Properties (BRP, $18) is well positioned: More than 80% of its Canadian assets are in oil-sands-rich Alberta. The Calgary company has owned most of its land for years but carries the value of that property on its books at cost. If the shares traded in line with Brookfield’s peers, they would triple.
With growth in China and other emerging markets slowing, buying shares in Joy Global (JOY, $64), one of the world’s biggest coal-mining-equipment companies, might seem crazy. But the stock, down 31% from its January 2012 high, more than reflects the slowdown. Joy’s stable maintenance and service business -- 60% of revenues -- is worth about $50 a share. If the global economy were just slightly stronger, its new-equipment business would be worth about the same. Despite growing use of natural gas in the U.S., worldwide construction of new coal plants remains strong. Joy Global shares could easily see $100 again in the coming year.
When American International Group (AIG, $33) announced strong third-quarter results, CEO Robert Benmosche said the insurer might not buy back any more AIG shares held by the U.S., as it had earlier said it might. The stock sank on the news, but investors missed the bigger picture. AIG trades at about 50% of its book value of $70 per share, while its peers typically trade at about book value. AIG could eventually earn $6 per share and trade at, or close to, its rising book value.
Columnist Andrew Feinberg manages a New York City–based hedge fund called CJA Partners.
Kiplinger's Investing for Income will help you maximize your cash yield under any economic conditions. Subscribe now!
-
Stocks Chop as the Unemployment Rate Jumps: Stock Market TodayNovember job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.
-
Should You Renew Your CD?With rate cuts impacting earnings, we examine if now is a wise time to renew CDs.
-
7 Ways to Plan Now to Save on Medicare IRMAA Surcharges LaterUnderstand the critical two-year lookback period and why aggressive planning before you enroll in Medicare is the most effective way to minimize IRMAA.
-
Why This Hedge-Fund Manager Is Shutting Downinvesting Now I plan to invest a chunk of the family portfolio in index funds—oh, the horror!
-
Know When to Sell a Stockinvesting Don't let a stock's stumbles blind you to its long-term potential.
-
The Secret to Safely Investing in Biotech
investing Seth Klarman was prescient in recognizing that the genomics revolution would supercharge the biotech industry.
-
Profit from Following Activist Investors
investing When investors like Carl Icahn and Bill Ackman turn the heat on management, shareholders stand to benefit.
-
Doubling Down on a Falling Stock
stocks Buying more shares makes sense when nothing about a company has changed except the price of its stock.
-
Andrew Feinberg's 6 Stock Picks for 2015
investing Bank of America has made great progress in cutting costs and settling legal claims for shoddy mortgage securities.
-
Promising Bargains in Biotech Stocks
investing What I like about BioDelivery Sciences is not so much that there are many ways to win as that there are almost no ways to lose.
-
Time-Tested Advice for Long-Term Investorsinvesting Learn from the Kahns, ultra-patient (and successful) value investors who often hold stocks for 20 years.
